12.00
+0.78(+6.95%)
Currency In USD
| Previous Close | 11.22 |
| Open | 11.36 |
| Day High | 12.33 |
| Day Low | 11.4 |
| 52-Week High | 18.2 |
| 52-Week Low | 9.24 |
| Volume | 3.96M |
| Average Volume | 1.57M |
| Market Cap | 3.75B |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 10.29 |
| Moving Average 200 Days | 10.64 |
| Change | 0.78 |
Data not available
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
– City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of Hearing Loss Among Patients Rec
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
GlobeNewswire Inc.
Dec 02, 2025 12:01 PM GMT
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alon
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2025 10:59 AM GMT
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the P